Hot Performing Stocks To Own Right Now

In Johnson & Johnson news, the stock is down 1.3% over the last five trading days, and that makes this the perfect time to buy this dividend aristocrat…

The pullback was caused by two analysts downgrading Johnson & Johnson (NYSE: JNJ) on July 21, but analysts simply don’t know how to value JNJ stock.

BTIG Research downgraded JNJ from “Neutral” to “Sell” because it doesn’t think Johnson & Johnson will be able to successfully execute its medical device acquisition.

Alembic Global Advisors downgraded the company from “Neutral” to “Underperforming” but didn’t release its rationale.

Hot Performing Stocks To Own Right Now: TESARO, Inc.(TSRO)

Advisors’ Opinion:

  • [By Todd Campbell]

    The PARP battle is on. Following news that AstraZeneca’s (NYSE:AZN) PARP-inhibiting cancer drug Lynparza delivered a big win in phase 3 studies, all eyes now shift to how a potential Food and Drug Administration approval for Lynparza will reshape the commercial opportunity for competitor Tesaro Inc. (NASDAQ:TSRO).

  • [By Ben Levisohn]

    Shares of Tesaro (TSRO) are soaring today after the biotech company reported positive data for its treatment of ovarian cancer over the weekend. Credit Suisse analyst Alethia Young and team contend that “M&A remains in focus” for Tesaro following the data:

    Getty Images

    We are increasing our target price to $122 from $90 as we move to an M&A DCF valuation. We were at ESMO this weekend, and we believe the big takeaway on Tesaro data is that it works broadly in all 2L ovarian populations and safety looks solid. We also think the robustness of this data bodes well from PRIMA and QUADRA but are maintaining our POS here. We have looked at our model and also adjusted durations in first-line. We think Tesaro remains one of the most attractive and de-risked cancer assets in our landscape and the company has been cited in major press sources as a takeout target (Bloomberg, Investor Business Daily).

    We think M&A remains in focus for Tesaro. Our M&A DCF valuations range from $122 to $157 by our model. We have also built models for other cancers like NSCLC, SCLC, prostate, and others where PARP might be impactful. We assume 0% POS for now but we conservatively see at least another $1B in sales from PARP expansion. Tesaro has been cited in the press as a potential M&A target and is a company we frequently hear mentioned as a target from our conversations. We think the demand for late stage oncology assets is high, especially in the PARP space given the potential for activity across a range of tumors. For a large Pharma player who already has an oncology salesforce and large R&D infrastructure we could see SG&A synergies of 50-75% and R&D synergies of 15-30%. In our base case TSRO P&L we model a tax rate of 30% so there could be synergies here as well. Two additional key swing factors which might be included in a CVR are how much expansion from PARP in other cancers and immuno-oncology…

    Ex M&A,

  • [By Todd Campbell]

    Tesaro’s (NASDAQ:TSRO)ovarian cancer drug, niraparib, will begin competing for prescriptions earlier than expected. Niraparib, which will be sold under the brand name Zejula, notched FDA approval on Monday, more than three months ahead of its June 30 decision date. The early approval setsTesaro up for a fierce battle for market share withAstraZeneca (NYSE:AZN)and Clovis Oncology (NASDAQ:CLVS), both of which market drugs that work similarly to Zejula.

  • [By Ben Levisohn]

    Look out below! Shares of Tesaro (TSRO) have dropped more than 10% this afternoon after AstraZeneca (AZN) released stronger-than-expected Phase 3 trial data on a its ovarian cancer treatment.

    Agence France-Presse/Getty Images

    The Street’sAdam Feuerstein has the details on AstraZeneca’s strong data and its impact on Tesaro:

    AstraZeneca’s (AZN) PARP inhibitor Lynparza delayed the recurrence of ovarian cancer by more than two years compared to a placebo, according to results from a phase III study presented Tuesday.

    The strong benefit observed with Lynparza as ovarian cancer maintenance therapy exceeded investor expectations and bolsters AstraZeneca against a competing PARP inhibitor from Tesaro (TSRO).

    Feuerstein also notes that AstraZeneca’s data could be good newsClovis Oncology (CLVS), which also had a PARP inhibitor approved recently, if it means that its drug could work as well as Astra’s.

    In February, Leerink cut Tesaro, arguing that the rally in its shares due to a potential takeover had run too far. Will it still be a takeover target?

    Shares of Tesaro have dropped 14% to $148.01 at 3:28 p.m. today, while AstraZeneca has gained 1.1% to $30.41, and Clovis Oncology has jumped 9.8% to$66.55.

    UPDATE:Piper Jaffray’sSteven Breazzano andJoshua Schimmer note that the AstraZeneca data shows that PARPs are “more similar than different.” They explain:

    This afternoon AstraZeneca (covered by PJC analyst Richard Purkiss) reported the detailed results from the SOLO-2 maintenance study of Lynparza in 2L+ ovarian cancer. The detailed data highlights a PFS benefit of 14 months (investigator assessed, and primary endpoint) and 25 months (blinded central review) over placebo, and favorable hazard ratio of 0.30 and 0.25, respectively, confirming our view that the PARP’s are more similar than different. As such, we believe this provides a favorable readth

  • [By Ben Levisohn]

    Guggenheim’s Tony Butler and Kaitlin Sandor argue that Gilead Sciences (GILD) should buy Syndax Pharmaceuticals (SNDX), Corvus Pharmaceuticals (CRVS), and Tesaro (TSRO) to solve its problem of slowing sales:

Hot Performing Stocks To Own Right Now: JinkoSolar Holding Company Limited(JKS)

Advisors’ Opinion:

  • [By Lisa Levin]

    JinkoSolar Holding Co (NYSE: JKS) dropped 9.88% to $16.87 after the company announced the offering of 3,500,000 American Depositary Shares.

    Fuwei Films (Holdings) Co (NASDAQ: FFHL) dropped 9.66% to $1.30. Fuwei Films’ trailing-twelve-month ROE is -10.85%.

  • [By Elizabeth Balboa]

    First Solar, Inc (NASDAQ: FSLR) was trading down 3.7 percent Monday, while JA Solar Holdings Co., Ltd. (ADR) (NASDAQ: JASO) was down 0.8 percent, SunPower Corporation (NASDAQ: SPWR) 4.4 percent, Canadian Solar Inc. (NASDAQ: CSIQ) 5.2 percent and JinkoSolar Holding Co., Ltd. (NYSE: JKS) 4.4 percent.

  • [By Paul Ausick]

    But the real news is the near vertical trajectory in share prices for the two stocks. This could be another manifestation of the markets hunger for some momentum plays, as we noted earlier this morning the bump to share prices for both JinkoSolar Holding Co. Ltd. (NYSE: JKS) and Shutterstock Inc. (NASDAQ: SSTK), both of which held secondary share sales this morning.

  • [By Lisa Levin]

    In trading on Monday, energy shares fell by 0.59 percent. Meanwhile, top losers in the sector included JinkoSolar Holding Co., Ltd. (NYSE: JKS), down 8 percent, and Teekay Offshore Partners L.P. (NYSE: TOO) down 7 percent.

Hot Performing Stocks To Own Right Now: Xcel Energy Inc.(XEL)

Advisors’ Opinion:

  • [By Shauna O’Brien]

    Jefferies announced on Wednesday that it has raised its rating on Xcel Energy Inc (XEL).

    The firm has upgraded XEL from “Hold” to “Buy,” and has raised the company’s price target from $31 to $32.50. This new price target suggests a 15% upside from the stock’s current price of $27.72.

    Analyst Paul B. Fremont commented: “The stock is currently trading at an 8% P/E discount to our 2015E group average multiple.”

    “Despite a difficult political environment in Minnesota the company was able to achieve a reasonable outcome in its NSP-Minnesota rate case,” the analyst added.

    Looking forward, the firm has increased its FY2014 outlook from $1.95 to $2.00 per share.

    Xcel Energy shares were mostly flat during pre-market trading Wednesday. The stock has been mostly flat YTD.

Leave a Reply

Your email address will not be published. Required fields are marked *